The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Name: The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD
Published: 2022
License: Public Domain

University Medical Center Groningen · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

chronic death dialysis heart-failure kidney-failure

kidney disease, chronic, renal transplant failure, heart failure, kidney failure, death, advanced ckd, dialysis, kidney transplant, all-cause mortality, hospitalization for heart failure, dapagliflozin, interventional

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

Related documents